科伦博泰生物-B：Data release at ASCO further confirmed SKB264’s potential

M N 6 Jun 2024 CMB International Global Markets | Equity Research | Company Update Kelun-Biotech (6990 HK) Data release at ASCO further confirmed SKB264’s potential  Promising efficacy of SKB264+A167 in 1L NSCLC. SKB264 (Q3W)+A167 Target Price HK$246.13 (PD-L1)’s 15.4 months of mPFS in 1L NSCLC was much better than the SoC – (Previous TP HK$200.77) 9.0 months mPFS of Keytruda+chemo in KEYNOTE189 and 9.7 months mPFS Up/Downside 35.8% of tislelizumab+chemo in RATIONALE304. SKB264’s Ph3 dose of Q2W could Curr ...